A Phase 2 interventional study of HM11260C and liraglutide in Type 2 Diabetes, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-08-09.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Hanmi Pharmaceutical Company Limited.
Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 2, and was the 2nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited are open now, in 2 countries. Recruiting first, the newest first:
Hanmi Pharmaceutical Company Limited · Sites in United States
Ages 18–75
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 254 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 10 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07379333Phase 3Hanmi Pharmaceutical Company LimitedA Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin | 2027-11 |
| NCT07527650Hanmi Pharmaceutical Company LimitedStudy to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
Drug: HM11260C
Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
Drug: HM11260C
Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
Drug: HM11260C
Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
Drug: HM11260C
Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
Drug: HM11260C
Weekly administration of placebo by subcutaneous injection for 12 weeks
Drug: Placebo
Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
Drug: liraglutide
HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Also known as: LAPS-Exendin-4
Liraglutide is a GLP-1 agonist.
Also known as: Victoza
Placebo
Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks
Time frame: Up to 127 days
Fasting plasma glucose levels (FPG)
Time frame: Up to 127 days
7-point glucose profile
Time frame: Up to day 127
Other glycaemic control parameters
Time frame: Up to day 127
Serum lipid profile
Time frame: Up to day 127
Body weight
Time frame: Up to day 127
Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%
Time frame: Up to 127 days
Assess the safety and tolerability of HM11260C
Time frame: Up to day 127
Assess the immunogenicity of HM11260C
Time frame: Up to day 127
The record gives a start of Jan 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efpeglenatide
Hanmi Pharmaceutical Company Limited →